Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The BioNTech scientist said his vaccine can “bash the virus over the head”.
There have been some concerns over the accuracy of COVID-19 rapid antigen tests—the clinical diagnostic tests that evaluate for active infections by testing for the presence of the virus’s antigens.
A recent study found that Vitamin D deficiency may be associated with an increased COVID-19 risk.
A study recently conducted at Mayo Clinic showed that dysfunctional Tissue Resident Memory (TRM) CD8 T cells are actually working against the elderly, reducing immunity and enabling residual chronic lung issues after respiratory infections such as COVID-19.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace recently spoke with Dr. James Garner, CEO of Kazia Therapeutics, an oncology company that is focused on the development of cancer drugs.
Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.
After months of urging the public to wear masks and facial coverings to help stop infected people from spreading COVID-19, the Centers for Disease Control and Prevention now states in newly released guidance that masks also protected the mask wearer from being infected.
5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited.
San Francisco-based Vir Biotechnology and its chief executive officer, George Scangos, believe it has a terrific antibody therapy against SARS-CoV-2, the virus that causes COVID-19. But is it too late to the game?